Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MCRB - Seres Therapeutics, Inc.
Market Cap 620.32M P/E - EPS this Y -16.90% Ern Qtrly Grth -
Income -82.68M Forward P/E -3.39 EPS next Y 26.00% 50D Avg Chg -2.00%
Sales 126.85M PEG 0.01 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book N/A EPS next 5Y -134.00% 52W High Chg -49.00%
Recommedations 2.70 Quick Ratio 1.20 Shares Outstanding 151.45M 52W Low Chg 13.00%
Insider Own 5.67% ROA -15.74% Shares Float 119.55M Beta 1.93
Inst Own 56.72% ROE - Shares Shorted/Prior 22.74M/17.63M Price 4.85
Gross Margin 2.57% Profit Margin -65.18% Avg. Volume 2,589,375 Target Price 3.45
Oper. Margin -60.70% Earnings Date Aug 6 Volume 1,415,031 Change 0.41%
Healthcare | Biotechnology | United States
About Seres Therapeutics, Inc.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics, Inc. News
06/07/24 Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/24 Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
06/06/24 Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
06/06/24 Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
05/13/24 Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
05/09/24 Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
05/09/24 Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
05/08/24 Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
05/08/24 Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
05/06/24 Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
04/09/24 Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
03/28/24 Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
03/13/24 11 Oversold NASDAQ Stocks To Buy Right Now
03/13/24 11 Oversold Healthcare Stocks To Buy Right Now
03/07/24 Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript
03/06/24 Q4 2023 Seres Therapeutics Inc Earnings Call
03/05/24 Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
03/05/24 Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
02/28/24 Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
02/27/24 Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
MCRB Chatroom

User Image MC428 Posted - 29 minutes ago

@Bfunk17 @Geekinvestor @DTT10 Alright so I went and checked recent asset sales from some other publicly listed companies. Yes $MCRB needs to prepare and file a proxy statement with the SEC, for a shareholder vote, but that isn't confidential. As soon as they file it it is available to the public, which has always been my understanding. Some weeks later they should announce a date for the special meeting for shareholders to vote via a filing/PR. So currently Seres has not yet filed the required proxy statement with the SEC, but that should be imminent if they truly want to close this thing within 90 days. ContextLogic (former ticker WISH) is a recent example, albeit not a bio but that doesn't matter. They PR'd an asset sale deal on 2/12 and files the proxy statement with th SEC the same day. PR for the special meeting for the vote was PR'd in mid March, presumably after the SEC signed off on their proxy.

User Image Geekinvestor Posted - 1 hour ago

$MCRB looks like I might have gotten the steps for the asset sale mixed up. Someone more knowledgeable can comment. - Company first prepares a proxy statement (Schedule 14A) - for this, they ought to have all the details of the transaction (let’s say a week from the MOU PR, June 6) - SEC review and clearance- typically 3 weeks (could be plus or minus a week) - PR on the terms (should happen immediately after the SEC clearance) - Distribution of Proxy materials / notice to shareholders (30 days is customary, but companies can do 20) - post meeting filings and closing (2 to 3 weeks) My point is two fold: one, without the terms of the transaction, they couldn’t have filed a 14A with SEC (if it’s an asset sale, the terms have been agreed upon) and two, we are still within the window of reasonableness and the 14A could be with the SEC waiting for clearance. In reality, they can release a PR as late as the week of July 15th and still close the transaction in 90 days.

User Image Whitenoise27 Posted - 4 hours ago

$MCRB you guys aren’t to good at this

User Image Zetsu17 Posted - 4 hours ago

$MCRB if anyone is suffering from depression or any kind of mental health issues, please consult biosensai. I have never seen someone else being so optimistic in life.

User Image MC428 Posted - 5 hours ago

$MCRB Hoping for deal terms this week. Want to dump this above $1 and move on.

User Image josephhons Posted - 7 hours ago

$AKBA $MCRB $CTMX bye bye money. It was nice knowing you. We shall meet again someday...maybe. haha. :)

User Image North60 Posted - 7 hours ago

$MCRB What happened right before close…? Did some a-hole simply dump at 0,7505?

User Image HuntingBenjmins Posted - 8 hours ago

$MCRB Who gave Bio the speed?

User Image BioSensai Posted - 8 hours ago

$MCRB Higher lows and higher highs. this is primed to run people and the month of July will be TRANSFORMATIVE

User Image BioSensai Posted - 8 hours ago

$MCRB Starting to actually think something big is coming our way and it is $20+

User Image BioSensai Posted - 8 hours ago

$MCRB In for the win. Chart looks primed to run to $3 overnight

User Image BioSensai Posted - 8 hours ago

$MCRB Not crazy at all. $20 could easily happen soon 1: VOWST sale details to Nestle out by mid July 2: SER-155 data out in July

User Image BioSensai Posted - 8 hours ago

$MCRB 50% after hour move is COMING

User Image BioSensai Posted - 8 hours ago

$MCRB LOOKING GOOD FOR BLASTOFF

User Image BioSensai Posted - 8 hours ago

$MCRB The road to $20+ in JULY in two easy steps 1: $300mm VOWST sale to erase all debt plus royalties 2: SER-155 data with strong efficacy for GvH disease

User Image BioSensai Posted - 8 hours ago

$MCRB $20 for me!!!

User Image BioSensai Posted - 8 hours ago

$MCRB This went from $2.9 to $32 overnight 2 years ago. Will do the same thing this July with SER-155 Efficacy data

User Image BioSensai Posted - 8 hours ago

$MCRB Sounds crazy until it doesn't. This could see $20 by end of July

User Image BioSensai Posted - 8 hours ago

$MCRB When VOWST details are out PLUS good SER-155 data, this could go nuts

User Image BioSensai Posted - 8 hours ago

$MCRB YES!!!!

User Image BioSensai Posted - 8 hours ago

$MCRB Volume coming in hot. July coming in hot. Spike me to $20+ daddy !!

User Image BioSensai Posted - 8 hours ago

$MCRB Oh and short squeeze will be epic. Could see $20+ if things go nuts

User Image BioSensai Posted - 8 hours ago

$MCRB This is so close to taking off. July is going to be HUGE

User Image BioSensai Posted - 8 hours ago

$MCRB Will be over $3 by July 20th

User Image BioSensai Posted - 8 hours ago

$MCRB July will be likely the biggest month of this company's history 1: Transaction details of VOWST. Expect over $300mm plus royalties 2: SER-155 Cohort 2 data with efficacy

User Image BioSensai Posted - 9 hours ago

$MCRB July is a HUGE month for this stock 1: VOWST buyout transaction details 2: SER-155 data release

User Image BioSensai Posted - 9 hours ago

$MCRB So ready for the buyout deets

User Image BioSensai Posted - 9 hours ago

$MCRB Will see over $5 very soon,. GET AT I!

User Image Electhim Posted - 9 hours ago

$MCRB I don’t think there will be an asset sale now. They were blowing smoke last PR. They’ll hold out for SER 155 data and add pressure on Nestle to make a fair deal. Prepare for long wait I could be wrong as we’re all guessing Short interest isn’t going down and shorts I’m certain are well informed of timeline

User Image BioSensai Posted - 9 hours ago

$MCRB News is soon. This is gonna be good

Analyst Ratings
Oppenheimer Perform Jun 7, 24
Canaccord Genuity Buy Jun 7, 24
Oppenheimer Outperform May 9, 24
Chardan Capital Buy May 8, 24
Oppenheimer Outperform Mar 6, 24
Chardan Capital Buy Mar 6, 24
Oppenheimer Outperform Jan 16, 24
Goldman Sachs Sell Nov 3, 23
Chardan Capital Buy Apr 28, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cloghessy Paula See Remarks See Remarks Oct 27 Option 0 9,418 48,588 10/31/23
Cloghessy Paula See Remarks See Remarks Oct 27 Sell 1.35 2,904 3,920 45,684 10/31/23
Shaff Eric D. CEO and President CEO and President Oct 27 Sell 1.35 8,552 11,545 115,620 10/31/23
Shaff Eric D. CEO and President CEO and President Oct 27 Option 0 27,838 124,172 10/31/23
Young Teresa L. See Remarks See Remarks Oct 27 Sell 1.35 2,907 3,924 8,454 10/31/23
Young Teresa L. See Remarks See Remarks Oct 27 Option 0 11,361 11,361 10/31/23
Arkowitz David Chief Financial Offi.. Chief Financial Officer Oct 27 Sell 1.35 4,066 5,489 175,756 10/31/23
Arkowitz David Chief Financial Offi.. Chief Financial Officer Oct 27 Option 0 13,209 179,822 10/31/23
DesRosier Thomas Chief Legal Officer.. Chief Legal Officer and EVP Oct 27 Option 0 13,501 118,047 10/31/23
DesRosier Thomas Chief Legal Officer.. Chief Legal Officer and EVP Oct 27 Sell 1.35 4,156 5,611 113,891 10/31/23
Ege David S. See Remarks See Remarks Oct 27 Sell 1.35 4,066 5,489 66,991 10/31/23
Ege David S. See Remarks See Remarks Oct 27 Option 0 11,361 71,057 10/31/23
von Moltke Lisa See Remarks See Remarks Oct 27 Sell 1.35 4,232 5,713 9,513 10/31/23
von Moltke Lisa See Remarks See Remarks Oct 27 Option 0 13,745 13,745 10/31/23
Henn Matthew R. See Remarks See Remarks Oct 27 Sell 1.35 3,886 5,246 56,356 10/31/23
Henn Matthew R. See Remarks See Remarks Oct 27 Option 0 12,623 60,242 10/31/23
Ege David S. See Remarks See Remarks Apr 27 Sell 5.19 7,038 36,527 59,696 05/01/23
Ege David S. See Remarks See Remarks Oct 27 Sell 7.93 5,012 39,745 46,734 10/31/22
Nutritional Health LTP Fund Ge... 10% Owner 10% Owner Jul 05 Buy 3.15 8,738,243 27,525,465 5,825,495 07/07/22